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Abstract
Background: The allochimeric MHC class I molecule [a1h1/u]-RT1.Aa that contains donor-type (Wistar Furth, WF; RT1u)
epitopes displayed on recipient-type (ACI, RT1a) administered in conjunction with sub-therapeutic dose of cyclosporine
(CsA) induces indefinite survival of heterotopic cardiac allografts in rat model. In vascularized transplantation models, the
spleen contributes to graft rejection by generating alloantigen reactive T cells. The immune response in allograft rejection
involves a cascade of molecular events leading to the formation of immunological synapses between T cells and the
antigen-presenting cells.
Methodology/Principal Findings: To elucidate the molecular pathways involved in the immunosuppressive function of
allochimeric molecule we performed microarray and quantitative RTPCR analyses of gene expression profile of splenic T
cells from untreated, CsA treated, and allochimeric molecule + subtherapeutic dose of CsA treated animals at day 1, 3 and 7
of post transplantation. Allochimeric molecule treatment caused down regulation of genes involved in actin filament
polymerization (RhoA and Rac1), cell adhesion (Catna1, Vcam and CD9), vacuolar transport (RhoB, Cln8 and ATP6v1b2), and
MAPK pathway (Spred1 and Dusp6) involved in tubulin cytoskeleton reorganization and interaction between actin and
microtubule cytoskeleton. All these genes are involved in T cell polarity and motility, i.e., their ability to move, scan and to
form functional immunological synapse with antigen presenting cells (APCs).
Conclusions: These results indicate that the immunosuppressive function of allochimeric molecule may depend on the
impairment of T cells’ movement and scanning ability, and possibly also the formation of immunological synapse. We
believe that these novel findings may have important clinical implications for organ transplantation.
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Introduction
Transplantation of genetically incongruous organ generates the
immune response, which may eventually result in the destruction
of the grafted tissue [1,2]. Because currently used immunosup-
pressants induce impairment of the recipient’s immune system, a
major goal in transplantation is to prevent rejection by inducing
tolerance while avoiding global immunosuppression [3,4].
The administration of MHC class I allochimeric molecule
[a1h1/u]-RT1.Aa that contains donor-type (Wistar Furth, WF;
RT1u) immunogenic epitopes displayed on recipient-type (ACI,
RT1a) sequences and produced by the alteration of the immuno-
dominant determinant in the a1-helical region of class I MHC
RT1.Aa to that of RT1.A1 and RT1.Au sequences induced
indefinite survival of heterotopic cardiac allografts in rats when
administered in conjunction with sub-therapeutic dose of cyclo-
sporine (CsA) [5–8]. The results of several studies indicate that the
soluble MHC class I proteins either directly inhibit T cell functions
by receptor blockade [9] or induce apoptosis of activated CD8+ T
cells [10]. Alterantively, the MHC molecules may modulate CD4+
T cells responses via phagocytosis and indirect presentation by
antigen-presenting cells [11]. However, the cellular and molecular
mechanisms underlying the immunosuppressive function of allochi-
meric [a1h1/u]-RT1.Aa molecule and the mechanism(s) by which
this immunosuppressant regulates gene expressions of host’s T cells
and induce allograft tolerance remains largely unknown.
In vascularized transplantation models, the spleen contributes to
graft rejection by generating alloantigen reactive T cells [12,13]. It
is well established that immune response relies on the ability of T
cells to move, scan and to form the immunological synapse with
the antigen presenting cells (APCs). Interaction of T cell with APC
involves: active migration towards the APCs, the adhesive contact
required to scan the surface of APC, and the polarization and
redistribution of cytoskeleton which allows the close apposition of
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with major histocompatibility complex [MHC; 14–25]. All these
functions require polarized cytoskeleton and proper segregation of
membrane, and adhesion and intracellular signaling proteins.
To find out which genes and molecular pathways are affected by
the allochimeric molecule treatment, we have analyzed, using
microarray and quantitative reverse transcription polymerase chain
reaction (qRT PCR), the quantitative and temporal patterns of gene
expression profile of splenic T cells in rats treated with allochimeric
[a1h1/u]-RT1.Aa molecule in conjunction with sub-therapeutic
dose of CsA in comparison to sub-therapeutic dose of CsA-treated
and untreated rats at post-transplantation day 1, 3 and 7.
Results
Overview of Gene Expression Profiles
Gene expression profiles were generated from ACI host splenic
T cells at 1, 3 or 7 days of post transplantation. Control trans-
planted animals received no treatment. Experimental transplanted
animals were treated with sub-therapeutic dose CsA in conjunc-
tion with allochimeric peptide or with sub-therapeutic dose of CsA
(see Material and Methods for details).
Principal Components Analysis
Principal component analysis (PCA) is a standard tool used in
modern data analysis, which simplifies (reduces) complex (multidi-
mensional) and confusing data sets to lower dimensions (less
complex). The goal of principal component analysis is to filter out
the irrelevant ‘‘noise’’ in existing data set and to identify the most
meaningful basis to present a data set. The principal components
analysis (PCA) was performed using Partek Genomics Suite. PCA
transforms the data to a new coordinate system such that the
greatest variance by any projection of the data comes to lie on the
first coordinate (called the first principal component), the second
greatest variance on the second coordinate, and so on. Those
characteristics of the data set that contribute most to its variance are
retained. When the T Cell microarray data were analyzed by PCA,
50% of the variation in samples was revealed in the first two
principal components. The type of treatment appeared to be the
most significant effect and the treatment time was another
significant variable (Fig. 1). The type of treatment appeared to be
the most significant effect since each treatment could be seen as
distinct groups. Both the untreated (Green) and the cyclosporine
treated (Red) samples seemed to form similar cluster shapes. For
example, the distance between each of the green ovoids is less than
the distance between green (untreated) and red ovoids (cyclosporine
treated). This suggests a greater variation due to treatment than
time after treatment for these two conditions. Cyclosporine plus
peptide (Blue) sample, on the other hand, was much more spread
out. This suggests another variable such as time after transplanta-
tion has an important role in this treatment condition. Treatment
time did appear to have some effect on the PCA for all treatment
conditions since the ovoids representing 7 days treatment samples
were always to the left of the 1 or 3 day treatments.
Figure 1. The principal component analysis (PCA). The allograft T Cell microarray data were analyzed by PCA using Partek Genomics Suite. 50%
of the variation in samples was revealed in the first two principal components. The first principal component is represented by the X axis and the
second principal component by the Y axis. Treatment type appeared to be major source of variation and is indicated by different colored ellipsoids.
Green, untreated; Red, CsA only; and Blue, CsA plus peptide. The numbers next to each ellipsoid indicate the number of days post transplantation
regardless of treatment type. The type of treatment appeared to be the most significant effect and the treatment time was another significant
variable. Each treatment could be seen as distinct groups. Both the untreated (Green) and the cyclosporine treated (Red) samples seemed to form
similar cluster shapes. Cyclosporine plus peptide (Blue) sample, on the other hand, was much more spread out. This could be due to another variable
such as time after transplantation. Indeed, treatment time did appear to have some effect on the PCA since the ovoids representing 7 day-treatment
samples were always to the left of the 1 or 3 days treatments.
doi:10.1371/journal.pone.0008020.g001
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Differential gene expression was determined in Partek Genomics
Suite with the criteria described in Materials and Methods. Since
post transplantation time also had an influence on the gene
expression profiles, we examined the effect of treatment on gene
expression for each day separately. Treatment with CsA and CsA +
peptide were compared with the corresponding untreated control
for that day (Table 1). Gene changes were divided into those that
wereunique to eachtreatment and those that werecommonto both
the CsA and CsA + peptide treatments. Overall, more than 80% of
these changes were genes down regulated compared to the
untreated control groups, which is expected considering the
immunosupressive function of CsA and CsA+peptide. The number
of gene expression changes associated with sub-therapeutic doses of
CsA was greatest at day 1 and quickly diminished by days 3 and 7.
On the other hand, gene expression changes unique to CsA +
peptide not only persisted but increased from 286 changes at day 1
to 683 changes at day 7 post treatment. Lists of individual gene
changes for each day can be found in the supplementary tables.
Since we were primarily interested in the genes involved in early
events of immune response associated with the immunosuppressive
function of allochimeric molecule, we focused our analysis on
genes differentially expressed due to CsA + peptide treatment
(Table 1, row 3). The increasing number of genes meeting the
criteria for differential expression suggested a persistent immunsu-
pression in the CsA + peptide treated animals. The increased
number of changes also suggested that there might be early and
additional late immunosuppressive effects of peptide treatment.
The overlap of CsA + peptide gene changes within the given days
can bee seen in Figure 2. There is surprisingly little overlap in
these changes. Only 32 genes were differentially expressed at both
1 and 3 days post-treatment with CsA + peptide. When day 3 and
7 post- teatment with CsA+peptide were compared, the 171 genes
common for both these days were differentially regulated. Only
one gene was differentially regulated at all three time points. That
gene was identified as an EST (AA800192) and was down
regulated approximately 2 fold at all three days. This EST has
sequence homologies with endogenous retroviral mRNA, LTR-
repeat sequences and MHC class I in rat. Considering the fact that
LTR repeats play a role not only in specific DNA rearrangement
but also act as a MHC I gene promoter cis-acting activation
response element [26–28] this finding is especially interesting.
Early Gene Changes Associated with CsA and CsA +
Peptide Treatments
The sub-therapeutic dose of CsA used in this study is not
effective in preventing heart allograft rejection in rat model [5–8].
The same dose of CsA is, however, much more effective when
administered in combination with the allochimeric molecule
[5–8]. The numbers of gene changes shown in Table 1 is
consistent with this idea. Initially (day 1), the CsA treatment
downregulates a significant number of genes, which are probably
the early responders, induced shortly after transplantation.
Although this down regulation does not persist in CsA treatment,
many gene changes do persist in the CsA + peptide treatment. Our
overall assessment is that majority of the changes are not really
persistent but rather can be divided into early and late changes.
The lists of differentially expressed genes may provide some insight
into the molecular mechanisms of action of these two immuno-
suppressants (Tables S1, S2, S3).
Most interestingly, among the genes down regulated at 1 day
and 3 days post transplantation in CsA + peptide treatment were
genes involved in actin filament polymerization and positive
regulation of protein polymerization (RhoA and Rac1; 29–33), cell
adhesion, and cell junction assembly and maintenance (Catna1,
Vcam, and CD9; 17, 23, 24, 34–36), vacuolar transport, vacuole
organization and biogenesis (Rhob, Cln8, ATP6v1b2; 37, 38–40)
and MAPK pathway genes [Spred1 and Dusp6; 41, 42] involved
in tubulin cytoskeleton reorganization and interaction between
actin and microtubule cytoskeleton (Table 2). The down
regulation of these genes was also confirmed independently by
qRT PCR method (Figures 3, 4, 5, 6). All these genes are directly
or indirectly involved in the pathways participating in T cell
polarization, scanning ability and the formation of the immuno-
logical synapse (see Discussion).
To identify additional functional related patterns from the
differentially expressed gene lists, we performed a pathway
analysis. This was done by comparison of our gene lists with
canonical KEGG pathways using ‘‘Pathway Express’’ [43].
Pathway Express ranks the probability of a pathway being
significantly affected with an impact factor [described in 43].
Based on an impact factor of three or greater we found 13 KEGG
pathways to be affected from the CsA treated differential expressed
gene list at day 1. In the CsA + peptide treatment at day 1 the
additional 6 pathways were found to be affected (Table 3). These
additional pathways also appeared to be consistent with the
pathways involved in T cell polarization, migration and immuno-
logical synapse formation and functions.
Table 1. Number of differentially expressed genes at 1, 3 and
7 days post-transplantation from both CsA and CsA plus
peptide treatments.
Treatment Day 1 Day 3 Day 7
CsA only 490 78 105
CsA and Pep Overlap
1 922 170 54
CsA and Pep only 286 584 683
1Indicates the number of differentially expressed genes common to both CsA
and CsA plus peptide treatment.
doi:10.1371/journal.pone.0008020.t001
Figure 2. Overlap of CsA plus Peptide differential gene
expression at 1, 3, and 7 days post-transplantation. The Venn
diagram was created from the lists of differentially expressed genes
unique to CsA plus peptide treatment (Table 1, row 3).
doi:10.1371/journal.pone.0008020.g002
Polarity and Motility Genes
PLoS ONE | www.plosone.org 3 December 2009 | Volume 4 | Issue 12 | e8020Comparison of 1 and 7 Day CsA + Peptide Treatments
Interestingly, pathway analysis revealed much more similarity
between 1 day and 7 days after treatment with CsA + peptide.
(Tables 3 and 4) Approximately one third of the significant
pathways were identical. These included NK and B Cell activation
pathways along with several of the associated signaling pathways,
Toll like receptor, VEGF, and MAPK. In addition, pathways
involved in cell adhesion remained significantly effected. Some of
the new pathways appearing at day 7 were also related to Cell
adhesion, Adherens junction, Focal adhesion and regulation of
actin cytoskeleton. Majority of these pathways are involved in T
cell polarity, migration and the formation of immunological
synapse with antigen presenting cells.
Discussion
Our study of T cell expression profile showed that the expression
levels of many genes either directly or indirectly involved in the
molecular pathways responsible for T cell polarization, movement,
scanning ability and the formation of the immunological synapse
are down regulated during CsA + allochimeric molecule treatment
when compared to CsA treatment alone or to the untreated control.
The generation of immune response requires several highly
specialized molecular and cellular events, which take place in
sequential manner. First there is a migration of T cells toward the
antigen presenting cells (APCs), followed by an initial adhesive
contact between T cell and APC which allows for the scanning of
APC surface by T cell, and finally the formation of the
immunological synapse i. e. the close apposition of T cell and
APC membranes necessary for the interaction between the T cell
receptors (TCR) and major histocompatibility complex (MHC).
The supramolecular spatial organization and highly dynamic
clustering of the molecules in the immunological synapse allows T
cell receptors to response to the antigen and to facilitate polarized
secretion of cytotoxic granules and cytokines. All these events
involve highly orchestrated polarization and rearrangements of
cytoskeleton, membranes, vacuolar/endosomal compartments and
cell adhesion and signaling molecules [14–21,23,25].
Table 2. T cell polarity and motility gene changes.
Primary Gene Name Affy Sequence ID Gene Description Accesion Number Fold Change
Day 1 Day3 Day 7
Actin Filament Polymerization
positive regulation of protein
polymerization
Rac1 1372513_at gb:AI103616:Weakly similar to plysia ras-related homolog A2 AI103616 21.532
Rac1 1391048_at Rattus norvegicus cDNA clone UI-R-BJ1-auh-f-06-0-UI 3,
mRNA sequence
BE101148 22.611
RhoA 1370130_at ras homolog gene family, member A NM_057132 21.548
Cell Junction Assembly and
Maintenance
cell adhesion
Cd9 1371499_at CD9 antigen AI227627 21.678
Cd36 1367689_a_at cd36 antigen AF072411 22.24 21.978
Cd36 1386901_at cd36 antigen NM_031561 22.15 22.369
Catna1 1371921_at Catenin (cadherin-associated protein) alpha 1 BM986272 21.805
Vcam1 1368474_at vascular cell adhesion molecule 1 NM_012889 21.727
Vacuolar Transport
lysosomal transport
vacuole organization
and biogenesis
RhoB 1369958_at ras homolog gene family, member B NM_022542 21.851
Atp6v1b2 1387664_at ATPase, H transporting lysosomal V1 subunit B2 sequence NM_057213 21.528
Cln8 1389791_at Ceroid lipofuscinosis, neuronal 8 AI179775 21.718
MAPK Activity
Dusp6 1382778_at gb:AI231350/UG=Rn.13146/UG_ TITLE=ESTs AI231350 21.563 21.506
Spred1 1377743_at Rattus norvegicus cDNA clone UI-R-DO0-ciw-p-11-0-UI 3,
mRNA sequence
BI292687 21.791 21.629
Spred1 1374700_at Rattus norvegicus cDNA clone UI-R-BS2-bdg-c-03-0-UI 3,
mRNA sequence
BF388903 21.578
Regulation of Natural Killer
Cell Mediated Toxicity
Igsf4a 1379252_at Rattus norvegicus cDNA clone UI-R-BO0-ahn-c-08-0-UI 3,
mRNA sequence
AW522833 21.551 22.387
Igsf4a 1376657_at Immunoglobulin superfamily member 4A BE117767 23.343
doi:10.1371/journal.pone.0008020.t002
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involved in all of the above events, are down regulated in T cells
originating from allochimeric MHC molecule treated animals.
Rac1, RhoA and RhoB genes belong to the Rho family of
GTPases. Rho GTPases cycle between an inactive, GDP-bound,
and an active, GTP-bound state, and act like ‘‘molecular switches’’
controlling the dynamics of cell proliferation, movement, cyto-
skeleton and TCR signaling [29–33]. Engagement of the TCR has
been shown to lead to the activation of Rac1 and Rac2 [44].
Consistent with a key role for Rac proteins in TCR mediated
signaling, CD4+ T cells from Rac22/2 mice are defective in
TCR mediated proliferation and IL-2 and IFN-c production
[45,46]. TCR stimulation leads to the activation of RhoA, and
blocking RhoA activation has been shown to decrease production
of IL-2 [47]. In addition, it was shown that inhibition of ROCKs,
key effectors of RhoA, caused a decrease in T cell proliferation and
production of IL-2 and IFN-c, and resulted in prolonged survival
of cardiac allograft [48]. In the light of these data it is not
surprising that immunosuppressive function of allochimeric
molecule used in our study relies on the down regulation of genes
belonging to Rho GTPase cascade.
The signaling Rac/Rho cascade triggered by TCR engagement
is also tightly intertwined with the remodeling of cytoskeleton
essential for decreased T cell rigidity that enables closer contacts
between the T cell and the APC and the formation of
immunological synapse [49,50]. Rac and Rho are also involved
in the integrin-mediated adhesion between T cells and APCs [49],
control of actin polymerization at the T cell/ APC interface, and
in proper clustering of lipid rafts and TCR at the immunological
synapse [50,51,52]. In addition, Rho GTPases are involved in the
acquisition of a polarized morphology of T cells i.e. in the
processes that are critical for the movement and migration of T
cells [49,53,54]. Unlike Rac and RhoA, the RhoB is an immediate
early response gene, which has a short half-life [37], is associated
with the plasma membrane and endosomal compartments, and
similar to Cln8 (Ceroid-lipofuscinosis, neuronal 8) and ATP6v1b2
(ATPase, hydrogen-transporting, lysosomal, V1 subunit B, isoform
2) genes, it is involved in the trafficking of receptors and signaling
molecules through the vesicular/endocytic pathway [39,40].
Considering all of these data we believe that the immunosup-
pressive function of allochimeric molecule may depend on the
impairment of T cell motility and scanning ability, T cells
adhesion with APCs, and the proper TCR clustering, and possibly
also the formation of immunological synapse.
Another genes down regulated in allochimeric molecule
treatment are Catna1, Vcam and CD9, which are involved in
intercellular adhesion, interaction with cytoskeleton, signaling and
regulation of inflammatory response. Vcam-1 (vascular cell
adhesion molecule-1 also known as CD106) is a membrane
protein and an integrin ligand, which mediates leukocyte-
endothelial cell adhesion and signal transduction, and is an
important factor in the initiation of an inflammatory response
[35,55]. Indeed, conditional Vcam-1 mutant mice have an
impaired immune response [56], and the over expression of
Vcam-1 is associated with several chronic inflammatory diseases
[57,58]. In addition, VCAM-1 is linked to actin cytoskeleton in
Figure 4. qRTPCR of expression of Cln8 and RhoB in splenic T
cells. The expression of Cln8 (A) and RhoB (B) involved in vacuolar
transport, vacuole organization and biogenesis is highly down
regulated in rats treated with cyclosporine plus allochimeric molecule
(CsA +P).
doi:10.1371/journal.pone.0008020.g004
Figure 3. qRTPCR of expression of RhoA and Vcam in splenic T
cells. The expression of RhoA (A) belonging to the family of Rho
GTPases and inlvolved in the organization of cytoskeleton and T cell
polarity, and Vcam (B) involved in cell adhesion is highly down
regulated in rats treated with CsA plus allochimeric molecule (CsA+P).
doi:10.1371/journal.pone.0008020.g003
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cadherin-associated protein; Ctnna1) is an intracellular protein
that associates with cadherins and cytoskeleton and is required for
the formation and maintenance of functional intercellular
adhesion complex [34]. CD9 is a member of the tetraspanin
superfamily (which also includes MHC molecules). Tetraspanins
are known to be involved in cell adhesion, motility, and cell
differentiation and activation. CD9, which is expressed on most
mature and naı ¨ve T cells, associates with various cell surface
molecules including co-stimulatory CD5 molecule [36]. We
suggest that the down regulation of these three genes in
allochimeric treated animals maybe responsible for the impair-
ment in T cell/APC adhesion, T cell motility and immune
response.
Allochimeric molecule treatment also causes a down regulation
of Mitogen-activated protein kinases (MAPK) pathway genes
Dusp6 and Spred1. The Dusp6 (Dual specificity phosphatase 6) is
a phosphatase, which inactivates members of the mitogen-
activated protein (MAP) kinase superfamily (MAPK/ERK,
SAPK/JNK), which are associated with cellular proliferation
and differentiation. Recent studies on T cells indicate that Dusp5
and DuspP6 are induced by IL-2 [42]. A novel gene Spred-1
(Sproutyrelated Ena/VASP homology 1-domain-containing pro-
tein-1) is involved in the inhibition of the Ras/Raf-1/ERK
pathway impairing the growth-factor-mediated activation of
ERK1/2 kinases [41]. Studies of Spred1 expression in T cells
showed that Spred-1 is highly up regulated in the tumor-
infiltrating CD8
+ T cells and that TGF-b modulates the infiltrating
function of CD8
+ T cells via TCR signaling and Spred1 expression
[41].
In conclusion, the T cells gene expression changes described in
our studies indicate multiple protective influences of allochimeric
peptide and will provide basis for further studies aimed at
understanding of pathways and mechanisms involved in the
immunosuppression and heart graft survival.
Materials and Methods
Animals
Adult male inbred Wistar Furth (WF; RT1.Au) and ACI
(RT1.Aa) rats (180–250 gm) were purchased from Harlan Sprague
Dawely (Indianapolis, IN). Heterotopic cardiac transplants were
placed intra-abdominally as described previously [5]. There were
threeexperimentalgroups:1.Transplantation controlgroup without
any treatment, 2. Transplantation in the presence of sub-therapeutic
dose of CsA (acute rejection) which consisted of 3 day course of oral
cyclosporine delivered by gavage feed (CsA, 10 mg/kg/day; day
0–2). Transplantation in the presence of sub-therapeutic dose
of CsA supplemented with allochimeric molecule (CsA + peptide).
Allochimeric peptide [a1h1/u]-RT1.Aa (GenWay, San Diego CA;
1 mg/kg) was delivered through the portal vein into ACI
recipients of WF hearts at the time of transplantation in addition
to a 3 days course of oral cyclosporine delivered by gavage feed
(CsA, 10 mg/kg/day; day 0–2). All experiments were performed
according to the The Methodist Hospital Research Institute animal
Figure 5. qRTPCR of expression of ATP6v1b2 in splenic T cells.
The expression of ATP6v1b2 which is involved in vacuolar transport is
highly down regulated in rats treated with cyclosporine plus
allochimeric molecule (CsA +P).
doi:10.1371/journal.pone.0008020.g005
Figure 6. qRTPCR of expression of Spred 1 and Dsp6 in splenic
T cells. The expression of Spred 1 (A) and Dsp6 (B), which belong to the
MAPK pathway and regulate cellular proliferation and differentiation, is
highly down regulated in rats treated with cyclosporine plus
allochimeric molecule (CsA +P).
doi:10.1371/journal.pone.0008020.g006
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1.
Pathway Name Impact Factor
2 #Genes in Pathway #Input Genes in Pathway #Pathway Genes on Chip
Asthma 15.763 22 9 17
Hematopoietic cell lineage 14.948 76 17 68
Cell adhesion molecules (CAMs) 14.381 150 21 103
Graft-versus-host disease 12.854 59 10 28
Allograft rejection 12.135 61 10 30
Cytokine-cytokine receptor interaction 11.866 159 22 129
Authoimmune thyroid disease 9.259 69 9 33
Antigen processing and presentation 8.703 91 11 51
Type I diabetes mellitus 8.302 68 9 37
B cell receptor signaling pathway 7.221 63 10 51
Primary immunodeficiency 5.835 34 6 25
Natural killer cell mediated cytotoxicity 5.475 85 11 74
Complement and coagulation cascades 3.304 56 7 53
Additional CsA+ Peptide Pathways
Toll-like receptor signaling pathway 5.266 90 10 71
Leukocyte transendothelial migration 4.692 115 12 101
T cell receptor signaling pathway 4.435 92 10 80
GnRH signaling pathway 3.414 86 9 81
MAPK signaling pathway 3.233 241 19 224
VEGF signaling pathway 3.099 66 7 60
1Differential expression based on the criteria described in ‘‘Material and Methods’’ from both the CsA and CsA plus peptide treatment groups.
2Impact factor calculated in Pathway Express [52].
3Number of differentially expressed genes associated with the KEGG pathway.
doi:10.1371/journal.pone.0008020.t003
Table 4. KEGG pathways overrepresented in CsA plus peptidetreatment at day 7 post-transplantation
1.
KEGG Pathway Impact Factor
2 # of Genes in Pathway #Differentially Expressed Genes # Genes on Chip
Adherence junction 10.601 71 1 64
VEGF signaling pathway 8.912 66 3 60
Natural killer cell mediated cytotoxicity 6.32 85 2 74
Focal adhesion 6.311 179 2 163
B cell receptor signalling 5.602 63 2 51
Axon guidance 5.18 113 2 93
Pancreatic cancer 4.7 71 1 62
Fc epsilon RI signaling pathway 4.642 70 1 68
Day 7 Wnt signaling pathway 4.601 124 2 112
Reguation of actin cytoskeleton 4.135 194 1 170
MAPK signaling pathway 4.096 241 1 224
Renal cell carcinoma 3.746 68 1 62
Biosynthesis of unsaturated fatty acids 3.695 23 1 20
Toll-like receptor signaling pathway 3.622 90 1 71
Colorectal cancer 3.61 79 1 72
SNARE interactions in vesicular transport 3.564 36 1 31
Cell adhesion molecules(CAMs) 3.284 150 1 103
1Differential expression based on the criteria described in ‘‘Material and Methods’’ from only the CsA plus peptide treatment group.
2Impact factor calculated in Pathway Express [52].
doi:10.1371/journal.pone.0008020.t004
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and Use of Laboratory Animals’’ (DHHS publication No. (NIH)
85–23 Revised 1985). The Institution also accepts as mandatory the
PHS‘‘PolicyonHumaneCareand UseofLaboratoryAnimals’’and
NIH ‘‘Principles for the Utilization and Care of Vertebrate Animals
Used in Testing, Research and Training.
T cells Isolation and FACS Analysis
Spleens from ACI host rats were harvested at 1, 3 and 7 days
post-transplantation. Cell suspension was made by passing spleen
through a cell strainer using 3cc syringe. Cells were treated with
lysing reagent (Becton Dickenson ) to remove the red cells and
then washed twice with complete media (10%Fcs/1640RPMI). T
cell population was purified via a positive T cell isolation kit using
magnetic anti-T cell micro beads (Miltenyl Biotech) and purity of
T cells was confirmed by FACS analysis i.e. T cells were stained
with BD Pharmingen (Franklin Lakes, NJ) reagents including
FITC-conjugated mouse anti- rat CD3 and CD4 antibodies for
15 minutes at the room temperature and then washed three times
with PBS and analyzed using FACScan flow cytometer (Becton
Dickenson, San Jose, CA).
RNA Isolation
For RNA isolation isolated T cells were pelleted, immediately
placed in RNA Later (Applied Biosystems/Ambion, Austin, TX)
and after overnight infiltration at 4uC they were kept in RNA
Later at 270uC until the isolation of total RNA. T cell pellets were
homogenized using a TissueLyser (Qiagen, Valencia, CA) and
RNA was isolated using the RNeasy Mini Kit (Qiagen, Valencia,
CA) according to the manufacturer’s recommendations. The
quantity, purity and integrity of RNA were evaluated using a
NanoDrop ND-1000 spectrophotometer (Nanodrop Technolo-
gies, Wilmington, DE) and an Agilent Bioanalyzer (Agilent
Technologies, Palo Alto, CA).
Quantitative RT PCR
Total RNA was isolated from purified spleenic T cells using
RiboPure kit (Applied Biosciences, Foster City, CA). Comple-
mentary DNA (cDNA) was made using High Capacity cDNA
Reverse Transcription Kit (Applied Biosciences, Foster City, CA).
The cDNA was used to determine the expression levels of house
keeping actin b (ACTb) gene and gene of interest. Total RNA
(1000 ng) was reverse transcribed (RT) and PCR amplified using
the High Capacity cDNA Reverse Transcription Kits (Applied
Biosystems) according to the manufacturer’s protocol. The RT
reaction consisted of a 10 min incubation at 25uC, 120 min
incubation at 37uC, followed by a 5 min 85uC termination step,
and the resulting complementary DNA (cDNA) was stored at 2
20uC. For Real time PCR amplification samples were run in
duplicate and only 1 gene was analysed per reaction. The cDNA
template reaction contained Assay On Demand Gene Expression
primers (see below; Applied Biosystems, Foster City, CA) and
TaqManH Fast Universal PCR no AmpErase UNG master mix
(Applied Biosystems, Foster City, CA). Reactions were heated to
95uC for 10 min, followed by 40 amplification cycles of 95uC for
15 s and 60uC for 1 min using Applied Biosystems 7500 Standard
System. The amount of target mRNA relative to housekeping gene
mRNA was expressed as fold incerase /decrease. Relative changes
were measured using real time PCR in the 7500 Fast or Standard
Real Time PCR System (version 1.3.1). To calculate the relative
quantity (RQ) of particular gene, 2-delta delta ct method
implemented in the software was used. The data are presented
as the fold change (RQ values) in gene expression level normalized
to endogenous reference gene.
PCR Primers
All PCR primers were purchased from SABiosciences (Frederick,
MD, USA): Spred 1, cat #PPR55168; Vcam, cat#PPR45334;
RhoA, cat# PPR56555A; RhoB, cat# PPR42656A; Rac, cat
#PPR48291A;CD9, cat# PPR42666A;Catna,cat# PPR48584A;
Cln8, cat# PPR42624A; ATP6v1b2, cat# PPR44008A; Dusp6,
cat# PPR43415.
Microarray
The microarray hybridization and analysis were performed by
Cogenics (Morrisville, NC) according to the manufacturer’s
protocol (Affymetrix, Santa Clara, CA). Total RNA from each
sample was converted to double-stranded cDNA with the
BioarrayTM Single-Round RNA Amplification and Labeling
Kit (Enzo Life Sciences), Double-stranded DNA purified with
Purification Kit (Enzo Life Sciences was ttranscribed in vitro using
the BioarrayTM HighYieldTM RNA Transcript Labeling Kit
(Enzo Life Sciences). For each sample, biotinylated cRNA spiked
with bioB, bioC, bioD and cre (Hybridization Control) was
hybridized to an Affymetrix Rat 230 2.0 Microarray for 16 hours
at 45uC. After hybridization, washing and staining, arrays were
scanned with an Affymetrix GeneChipH Scanner 3000. Quality
checks and data analyses were performed using Affymetrix
GeneChip Operating Software (GCOS) and Expression Console.
All microarray data reported in the manuscript are described in
accordance with MIAME guidelines.
Microarray Data Analysis
The processed image file of the Affymetrix Rat 230 2.0 array
contains over 31,000 probe sets representing approximately
28,700 well-substantiated rat genes (Affymetrix; www.affymetrix.
com). The probe set level data were analyzed with either Rosetta
Resolver Gene Expression Data Analysis System (Rosetta,
Seattle, WA) or Partek Genomics Suite, version 6.4, build
6.09.0129 (Partek, St. Louis, MO). The criteria for identification
of differentially expressed transcripts was a log ratio p-
value,0.001, an absolute fold change greater than 1.5, and a
log (10) intensity measurement .21.6. Enrichment of biological
pathways for differentially expressed genes was determined using
Pathway Express [43]. The microarray data used in this study
were deposited in the National Center for Biotechnology
Information (NCBI) Gene Expression Omnibus (GEO) with the
accession number GSE15074 (www.ncbi.nlm.nih.gov/projects/
geo).
Supporting Information
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XLS)
Author Contributions
Conceived and designed the experiments: WL MK RMG. Performed the
experiments: NT TSS MG. Analyzed the data: WL EGB MK RMG.
Wrote the paper: MK. Performed heart transplants in rats: YG.
Polarity and Motility Genes
PLoS ONE | www.plosone.org 8 December 2009 | Volume 4 | Issue 12 | e8020References
1. Dunn DL (1990) Problems related to immunosuppression. Infection and malignancy
occurring after solid organ transplantation. Critical Care Clinics 6: 955–977.
2. Trivedi HL (2007) Immunobiology of rejection and adaptation. Trans Proc 39:
647–652.
3. Butcher GW, Howard JC (1982) Genetic control of transplant rejection.
Transplantation 34: 161–166.
4. Colovai AI, Renna-Molajoni E, Cortesini R, Suciu-Foca N (1996) New
approaches to specific immunomodulation in transplantation. Int Rev Immunol
13: 161–172.
5. Ghobrial RM, Hamashima T, Wang M, Stepkowski SM, Kahan BD (1996)
Induction of transplantation tolerance by chimeric donor/recipient class I
RT1.Aa molecules. Transplantation 62: 1002–1010.
6. Semiletova N, Shen X-D, Fishbein MC, Gao F, Slomowitz SJ, et al. (2003)
Posttransplant administration of allochimeric major histocompatibility complex
class-I-molecules induces true transplantation tolerance. Transplantation 75:
550–553.
7. Semiletova NV, Shen X-D, Baibakov B, Feldman DM, Mukherjee K, et al. (2005)
Inhibition of Chronic Rejection by Antibody Induced Vascular Accommodation
in Fully Allogeneic Heart Allografts. Transplantation 80: 1535–1340.
8. Singer JS, Mhoyan A, Fishbein MC, Shen X-D, Gao F, et al. (2001)
Allochimeric class I MHC molecules prevent chronic rejection and attenuate
alloantibody responses. Transplantation 72: 1408–1416.
9. Hausmann R, Zavazava N, Steinmann J, Muller-Ruchholtz W (1993)
Interaction of papain-digested HLA class I molecules with human alloreactive
cytotoxic T lymphocytes (CTC). Clin Exp Immunol 91: 183–188.
10. Zavazava N, Kronke M (1996) Soluble HLA class I molecules induce apoptosis
in alloreative cytotoxic T lymphocytes. Nature Med 2: 1005–1010.
11. Sayegh MH, Carpenter CB (1996) Role of indirect allorecognition in allograft
rejection. Int Rev Immunol 13: 221–229.
12. Chiffoleau E, Be ´riou G, Dutartre P, Usal C, Soulillou J-P, et al. (2002) Role for
Thymic and Splenic Regulatory CD4+ T Cells Induced by Donor Dendritic Cells
in Allograft Tolerance by LF15-0195 Treatment. J Immunol 168: 5058–5069.
13. Hall, BM (1982) Role of the Spleen in Cell-Mediated Cardiac Allograft
Rejection. Transplantation 33: 403–406.
14. Al-AlwanMM, LiwskiRS,Haeryfar SM,Baldridge WH, Hoskin DW, etal. (2003)
Cutting edge: Dendritic cell actin cytoskeletal polarization during immunological
synapse formation is highly antigen-dependent. J Immunol 171: 4479–4483.
15. Brossard C, Feuillet V, Schmitt A, Randriamampita C, Romao M, et al. (2005)
Multifocal structure of the T cell-dendritic cell synapse. Eur J Immunol 35:
1741–1753.
16. Davis DM, Dustin ML (2004) What is the importance of the immunological
synapse? Trends Immunol 25: 323–327.
17. Dustin ML (2007) Cell adhesion molecules and actin cytoskeleton at immune
synapses and kinapses. Curr Opin Cell Biol 19: 529–533.
18. Dustin ML (2008) Synaptic asymmetry to go. Cell 132: 733–734.
19. Dustin ML, Cooper JA (2000) The immunological synapse and the actin
cytoskeleton: molecular hardware for T cell signaling. Nature Immunol 1:
23–29.
20. Huang Y, Burkhardt JK (2007) T-cell-receptor-dependent actin regulatory
mechanisms. J Cell Sci 120: 723–730.
21. Ise W, Nakamura K, Shimizu N, Goto H, Fujimoto K, et al. (2005) Orally
tolerized T cells can form conjugates with APCs but are defective in
immunological synapse formation. J Immunol 175: 829–838.
22. Janssen E, Tabeta K, Barnes MJ, Rutschmann S, McBride S, et al. (2006)
Efficient T cell activation via a Toll-Interleukin 1 receptor-independent
pathway. Immunity 24: 787–799.
23. Pais-Correia PM, Thoulouze ML, Alcover A (2007) T cell polarization and the
formation of immunological synapses: from antigen recognition to virus spread.
Cur Immunol Rev 3: 170–188.
24. Rodriguez-Fernandez JL, Corbi AL (2005) Adhesion molecules in human
dendritic cells. Cur Op Invest Drugs 6: 1103–1111.
25. Sancho D, Vicente-Manzanares M, Mittelbrunn M, Montoya MC, Gordon-
Alonso M, et al. (2002) Regulation of microtubule-organizing center orientation
and actomyosin cytoskeleton rearrangement during immune interactions.
Immunol Rev 189: 84–97.
26. Choi S-Y, Van de Mark K, Faller DV (1997) Identification of a cis-Acting
Element in the Class I Major Histocompatibility Complex Gene Promoter
Responsive to Activation by Retroviral Sequences. J Virol 71: 965–970.
27. Matsuo MY, Nonaka M (2004) Repetitive elements in the major histocompat-
ibility complex (MHC) class I region of a teleost, medaka: identification of novel
transposable elements. Mech Dev 121: 771–777.
28. Yuhki N, Beck T, Stephens RM, Nishigaki Y, Newmann K, et al. (2003)
Comparative Genome Organization of Human, Murine, and Feline MHC Class
II Region. Genome Res 13: 1169–1179.
29. Adamson P, Etienne S, Couraud P-O, Calder V, Greenwood J (1999)
Lymphocyte migration through brain endothelial cell monolayers involves
signaling through endothelial ICAM-1 via a Rho-dependent pathway.
J Immunol 162: 2964–2973.
30. Becart S, Balancio AJC, Charvet C, Feau S, Sedwick, et al. (2008) Tyrosine-
phosphorylation-dependent translocation of the SLAT protein to the immuno-
logical synapse is required for NFAT transcription factor activation. Immunity
29: 704–719.
31. Gupta S, Fanzo JC, Hu C, Cox D, Jang SJ, et al. (2003) T cell receptor
engagement leads to the recruitment of IBP, a novel guanine nucleotide
exchange factor, to the immunological synapse. J Biol Chem 278: 43541–43549.
32. Ocana-Morgner C, Wahren C, Jessberger R (2009) SWAP-70 regulates RhoA/
RhoB-dependent MHCII surface localization in dendritic cells. Blood 113:
1474–1482.
33. Pernis AB (2009) Rho GTPase-mediated pathways in mature CD4+ T cells.
Autoimmun Rev 8: 199–203.
34. Nagafuchi A, Takeichi M, Tsukita S (1991) The 102 kd cadherin-associated
protein: similarity to vinculin and posttranscriptional regulation of expression.
Cell 65: 849–857.
35. Carrasco JL, Batista FD (2006) B-cell activation by membrane-bound antigens is
facilitated by the interaction of VLA-4 with VCAM-1. EMBO J 25: 889–899.
36. Toyo-oka K, Yashiro-Ohtani Y, Park C-S, Tai X-G, Miyake K, et al. (1999)
Association of tetraspanin CD9 with CD5 on the T cell surface: role of particular
transmembrane domains in the association. Intern Immunol 11: 2043–2052.
37. Kamon H, Kawabe T, Kitamura H, Lee J, Kamimura D, et al. (2006) TRIF–
GEFH1–RhoB pathway is involved in MHCII expression on dendritic cells that
is critical for CD4 T-cell activation. EMBO J 25: 4108–4119.
38. Lajoie-Mazenc I, Tovar D, Penary M, Lortal B, Allart S, et al. (2008) MAP1A
Light Chain-2 Interacts with GTP-RhoB to Control Epidermal Growth Factor
(EGF)-dependent EGF Receptor Signaling. J Biol Chem 283: 4155–4164.
39. Vantaggiato C, Redaelli F, Falcone S, Perrotta C, Tonelli A, et al. (2009) A
novel CLN8 mutation in late-infantile-onset neuronal ceroid lipofuscinosis
(LINCL) reveals aspects of CLN8 neurobiological function. Hum Mutat [Epub
ahead of print].
40. Satoh J, Nakanishi M, Koike F, Miyake S, Yamamoto T, et al. (2005)
Microarray analysis identifies an aberrant expression of apoptosis and DNA
damage-regulatory genes in multiple sclerosis. Neurobiol Dis 18: 537–550.
41. di Bari MG, Lutsiak MEC, Takai S, Mostbo ¨ck S, Farsaci B, et al. (2009) TGF-b
modulates the functionality of tumor-inWltrating CD8+ T cells through eVects
on TCR signaling and Spred1 expression. Cancer Immunol Immunother
EPUB.
42. Kovanen PE, Young L, Al-Shami A, Rovella V, Pise-Masison CA, et al. (2005)
Global analysis of IL-2 target genes: identification of chromosomal clusters of
expressed genes. Internat Immunol 17: 1009–1021.
43. Draghici S, Khatri P, Tarca AL, Amin K, Done A, et al. (2007) A systems
biology approach for pathway level analysis. Genome Research 17: 1537–1545.
44. Sanui T, Inayoshi A, Noda M, Iwata E, Oike M, et al. (2003) DOCK2 is
essential for antigen-induced translocation of TCR and lipid rafts, but not PKC-
theta and LFA-1, in T cells. Immunity 19: 119–129.
45. Li B, Yu H, Zheng W, Voll R, Na S, et al. (2000) Role of the guanosine
triphosphatase Rac2 in T helper 1 cell differentiation. Science 288: 2219–2222.
46. Yu H, Leitenberg D, Li B, Flavell RA (2001) Deficiency of small GTPase Rac2
affects T cell activation. J Exp Med 194: 915–926.
47. Angkachatchai V, Finkel TH (1999) ADP-ribosylation of rho by C3
ribosyltransferase inhibits IL-2 production and sustained calcium influx in
activated T cells. J Immunol 163: 3819–3825.
48. Tharaux PL, Bukoski RC, Rocha PN, Crowley SD, Ruiz P, et al. (2003) Rho
kinase promotes alloimmune responses by regulating the proliferation and
structure of T cells. J Immunol 171: 96–105.
49. Vicente-Manzanares M, Sa ´nchez-Madrid F (2004) Role of the cytoskeleton
during leukocyte responses. Nat Rev Immunol 4: 110–122.
50. Faure S, Salazar-Fontana LI, Semichon M, Tybulewicz VL, Bismuth G, et al.
(2004) ERM proteins regulate cytoskeleton relaxation promoting T cell-APC
conjugation. Nat Immunol 5: 272–279.
51. Villalba M, Bi K, Rodriguez F, Tanaka Y, Schoenberger S, et al. (2001) Vav1/
Rac-dependent actin cytoskeleton reorganization is required for lipid raft
clustering in T cells. J Cell Biol 155: 331–338.
52. Tskvitaria-Fuller I, Seth A, Mistry N, Gu H, Rosen MK, et al. (2006) Specific
patterns of Cdc42 activity are related to distinct elements of T cell polarization.
J Immunol 177: 1708–1720.
53. Lee JH, Katakai T, Hara T, Gonda H, Sugai M, et al. (2004) Roles of p-ERM
and Rho-ROCK signaling in lymphocyte polarity and uropod formation. J Cell
Biol 167: 327–337.
54. Nijhara R, van Hennik PB, Gignac ML, Kruhlak MJ, Hordijk PL, et al. (2004)
Rac1 mediates collapse of microvilli on chemokine-activated T lymphocytes.
J Immunol 173: 4985–4993.
55. Mobley JL, Ennins E, Shimizu J (1994) Differential activation-dependent
regulation of integrin function in cultured human T-leukemic cell lines. Blood
83: 1039–1050.
56. Leuker CE, Labow M, Mu ¨ller W, Wagner N (2001) Neonatally induced
inactivation of the vascular cell adhesion molecule 1 gene impairs B cell
localization and T cell-dependent humoral immune response. J Exp Med 193:
755–768.
57. van Dinther-Janssen AC, Horst E, Koopman G, Newmann W, Scheper RJ,
et al. (1991) The VLA-4/VCAM-1 pathway is involved in lymphocyte adhesion
to endothelium in rheumatoid synovium. J Immunol 147: 4207–4210.
58. Belmont HM, Buyon J, Giorno R, Abramson S (1994) Up-regulation of
endothelial cell adhesion molecules characterizes disease activity in systemic
lupus erythematosus. The Shwartzman phenomenon revisited. Arthritis Rheum
37: 376–383.
Polarity and Motility Genes
PLoS ONE | www.plosone.org 9 December 2009 | Volume 4 | Issue 12 | e8020